.... and not only that, Montrachet, the effectiveness of the combination in late stage sufferers (those previously given up as dead) is 83%.
And, there is yet another upside.... Grade 3 or higher treatment related adverse events is 10.1% in Keytruda alone, BUT is reduced to ZERO when combined with Cavatak!
It should make Cavatak worth heaps (imho)... heaps. Wake up market... and wake up Merck!
.... and not only that, Montrachet, the effectiveness of the...
Add to My Watchlist
What is My Watchlist?